Spectral AI Inc (MDAI) Quote

MDAI......................................................https://stockcharts.com/h-sc/ui?s=MDAI&p=W&b=5&g=0&id=p86431144783

GlobeNewswireMarch 13, 2024
DALLAS, March 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, March 27, 2024 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.

MDAI $3a cash machine $$$$

MDAI...READY FOR 3 DOLLA

MDAI $$$ Could see $10.00++..Float Crazy Low..

TRIM SOME FAT ABOVE 2.82

MDAI...BLOWING UP ABOVE THAT 4 HOUR CLOUD!!

MDAI..LOOKS LIKE 3 BUCKS COMING

MDAI..THERE IS THE 2.82 BREAK

LOW FLOAT SO SHE WILL MOVE FAST

LEVEL 2 NICE AND CLEAN SO FAR

MDAI...START YOUR ENGINES

Spectral AI Announces New US Government Contract to Further Accelerate the Development of the Handheld Version of DeepView™ Wound Imaging System

Source: GlobeNewswire Inc.

Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced a new contract with the Defense Health Agency (DHA) and the US Army Medical Material Development Activity (USAMMDA) that provides significant additional support for the development of the handheld version of DeepView™ Wound Imaging System called DeepView SnapShot® M.
This newly secured contract is valued at over $500,000 and will build on the previous awards from other U.S. Government Agencies focused on advancing the handheld, DeepView Snapshot® M, that bring this total for just the DeepView SnapShot® M to greater than $6 million. The ultimate goal of the contract and this targeted non-dilutive funding is to optimize the functionality and size of the device and to ensure its combat readiness. These optimizations will, in turn, increase the device’s potential for a portable, handheld version for home health care and related invaluable assistance to medical professionals in many settings.

“Spectral AI is proud to partner with DHA and the USAMMDA on this crucial initiative. This award further validates Spectral AI’s technology and the importance of a battlefield burn solution we are focusing on,” stated Pete Carlson, CEO of Spectral AI. “We firmly believe that this collaboration will make a profound impact, as the miniaturization of medical devices is essential for introducing innovative medical care to a wider range of clinical settings and patients. This development reaffirms Spectral AI's dedication to shaping the future of accessible medical care and solidifies its position as a trailblazer in AI-driven healthcare innovation.”

The Company has previously announced other significant non-dilutive financial support from the US Government that with this award announced today, now totals over $250 million, including $150 million awarded in the last six months.

About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.

MDAI 10Q. Due March 12

MDAI 10Q 2/27

$MDAI News: Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors
Spectral AI, Inc.
Mon, Feb 12, 2024, 8:00 AM EST

In This Article:
MDAI
+2.28%
MDAIW
Spectral AI, Inc.

The Company’s two largest stockholders holding approximately 45% of the Company’s outstanding shares have extended their lock-up agreements for an additional 180 days

DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024. Dr. DiMaio joins the Board as a non-executive member to fill the vacancy left by the departure of Mr. Michael Murphy.

Dr. Michael DiMaio is one of the Company’s founders and previously served as the Company’s Chief Executive Officer and Chairman of the Board of Directors from 2011 to 2020. In 2020, he exited his positions with the Company and amicably resolved a dispute that had arisen at that time. He is the Chief of Staff and a practicing board-certified general, cardiac and thoracic surgeon at Baylor Scott & White-The Heart Hospitals, one of the busiest cardiovascular programs in the United States. Currently the hospitals that he oversees are rated with the highest quality scores by the Society of Thoracic Surgeons, Society of Vascular Surgery, and the American College of Cardiology. He supervises more than 650 physicians across six facilities that perform approximately 25,000 cardiovascular procedures annually.

Dr. DiMaio earned his medical degree from the University of Miami and completed his internal medicine, general surgery, and cardiothoracic surgery residencies at Duke University Medical Center and performed research under an NIH-sponsored grant. He has been elected or served as a member on many distinguished medical organizations including the American Surgical Association, Society of Thoracic Surgeons, American College of Surgeons, American Association of Thoracic Surgery, American Heart Association, American Burn Association, International Society of Heart and Lung Transplantation, American Society of Transplant Surgeons, and the Southern Thoracic Surgical Association.

He has authored nearly 500 peer-reviewed publications and abstracts, and directs a research group that has produced over 1000 publications in medical journals that include JAMA, New England Journal of Medicine, Lancet, Science, and Circulation. Dr. Michael DiMaio has served as an editorial board member or reviewer for some the most prestigious medical journals in the world and has served as a grant reviewer for the National Institutes of Health (NIH), the American Heart Association, and the U.S. Department of Defense in an addition to serving on international medical guideline committees.

In clinical trials, he has been the principal investigator for numerous medical drugs and devices that have received FDA approval and commercialization. He has been awarded over $150 million funding from the NIH, the American Heart Association, the National Science Foundation, the U.S. Department of Defense, the Department of Health and Human Services, and the Biomedical Advanced Research Development Authority (BARDA). Currently, he oversees more than 120 clinical trials at the Baylor Scott & White Research Institute and serves as Chairman of the Cardiovascular Research Review Committee for the health care system.

"I am pleased to welcome back Dr. Michael DiMaio to Spectral AI’s Board of Directors," said Richard Cotton, Chairman of the Board of Directors. "Dr. DiMaio’s deep knowledge and application of innovative medical device technologies, decades of direct patient care, and experiences within some of the United States’ preeminent medical systems and current leadership make him uniquely qualified to support the planned commercialization and ongoing development of our DeepView™ System.”

"I have spent a great deal of my career developing technologies that improve patient outcomes while delivering tangible value across the healthcare spectrum and founded this company with the intent to fill the unmet clinical need for a decision-assist device to improve wound care management,” said Dr. DiMaio. “I believe that the Company’s AI-driven wound imaging and assessment technology platform is poised to deliver on those objectives, and I am very pleased to be in a position to help advance this exciting technology towards commercialization of current and future indication developments.”

The Company also announced that Dr. DiMaio and Erich Spangenberg, who together hold approximately 45% of the Company’s outstanding shares, have each agreed to an additional six-month extension of the current lock-up of their outstanding shares pursuant to the Registration Rights/Lock-Up Agreement entered into by each of them in connection with the Company’s business combination transaction in September 2023.

About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.

Forward Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

Contacts




Investors



Equity Group



Devin Sullivan

Conor Rodriguez

Managing Director

Analyst

dsullivan@equityny.com

crodriguez@equityny.com


Media



Russo Partners



David Schull



(858) 717-2310



david.schull@russopartnersllc.com

$MDAI #ArtificalIntelligence #AI sector growth - Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment in wound care. http://spectral-ai.com $JNJ $LLY

$MDAI #Nasdaq NEWS - Spectral AI to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference https://www.wsj.com/articles/spectral-ai-to-participate-in-the-2024-btig-medtech-digital-health-life-science-diagnostic-tools-conference-173ac0ec?reflink=mw_share_twitter
#BreakingNEWS #Nasdaq #2024Conference

$MDAI Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment in wound care. http://spectral-ai.com

$MDAI Making a nice move $2.28 +11.22% HOD $2.3199 in jeopardy.

With a 52-week range from 1.7900 to 19.5000, $MDAI showcases its resilience and growth trajectory, capturing the attention of investors
https://investors.spectral-ai.com/news-releases/news-release-details/spectral-ai-announces-publication-letter-shareholders

Good morning $MDAI Premarket numbers $2.19 + 6.83%

and so what

$MDAI On watch closely after hours and pre-market.

$MDAI Nice close $2.05 +5.67% HOD $2.12 RSI Curling Upwards.

$MDAI Spectral AI Announces Publication of Letter to Shareholders

DALLAS, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the publication of a Letter to Shareholders from the Company's CEO and Co-founder, Wensheng Fan, and Chairman of the Board, Richard Cotton.

The Letter to Shareholders addresses the Company's progress along multiple fronts as it continues to evolve from a late-stage development company towards commercialization of its AI-driven DeepView System. The Company believes that this proprietary platform technology can revolutionize the standard of care in wound assessment and treatment for burn and Diabetic Foot Ulcer ("DFU") indications.

Highlights of the Letter to Shareholder include:

-- The largest contract in the Company's history, a $149 million award from
BARDA that provides non-dilutive funding for ongoing product development
and procurement.

-- An expectation that, pending regulatory authorization in the US and UK,
the Company will generate revenue across four separate platforms covering
burn and DFU within the next three years, with the potential for initial
commercial revenue as soon as the second half of 2024.

-- FDA and UKCA marking of the Company's proprietary imaging technology,
DeepView Snapshot(R), as well as the recent submission of the Company's
predictive software, DeepView AI(R)-Burn, to the UK regulatory body for
UKCA marking.

-- Promising interim results for the Company's DFU Clinical Study and
multiple ongoing clinical trials designed to validate the DeepView System
for wound healing assessments, including the initiation of a pivotal
study in the US for Burn and an anticipated 1H 2025 submission to the FDA
for US approval for this indication.

-- Appointments that have added strength and depth to the Company's
management team and Board of Directors.
The Letter to Shareholders was filed on Form 8-K with the Securities and Exchange Commission and is available free of charge at www.sec.gov. A copy of the letter is also accessible at the Investor Relations section of the Company's website at https://investors.spectral-ai.com/.

About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by "Seeing the Unknown(R) " with its DeepView(R) System. DeepView(R) is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView(R) is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView(R) , visit www.spectral-ai.com.

Forward Looking Statements

Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company's strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words "estimates, " "projected," "expects," "anticipates," "forecasts," "plans," "intends, " "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" sections of the Company's filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

Contacts

Investors

Equity Group

Devin Sullivan

Managing Director

dsullivan@equityny.com

Conor Rodriguez

Analyst

crodriguez@equityny.com

Media

Russo Partners

David Schull

(858) 717-2310

david.schull@russopartnersllc.com

Press Release: https://www.marketwatch.com/press-release/spectral-ai-announces-publication-of-letter-to-shareholders-a9abe93c?mod=mw_quote_news_seemore

$MDAI #Nasdaq NEWS - Spectral AI to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference https://www.wsj.com/articles/spectral-ai-to-participate-in-the-2024-btig-medtech-digital-health-life-science-diagnostic-tools-conference-173ac0ec?reflink=mw_share_twitter
#BreakingNEWS #Nasdaq #2024Conference

MDAI new 52 week low

Clinical Decision Support for Diabetic Foot Ulcers
The Growing Problem of Diabetic Foot Ulcers
Diabetic Foot Ulcers (DFUs) are a problem that affects 9.1 million to 26.1 million patients worldwide.
Undiagnosed, misdiagnosed, or untreated DFUs, both complicate and extend length of care.
https://www.spectral-ai.com/wound-care-assessment/clinical-decision-suppport-diabetic-foot-ulcer/

$MDAI Multispectral Imaging in Diagnostic Medicine
Currently, there is a lack of diagnostic tools for determining tissue health.

Multispectral imaging allows the physician to extract intrinsic properties and structures of specific tissues which are not visible to the human eye.
https://www.spectral-ai.com/wound-healing-technologies/multispectral-imaging/

Pump n dump No 2

Spectral AI has received significant non-dilutive government funding totaling $251 million since 2019. $MDAI day’s range was 2.3200 - 3.7000 indicating an up-trend for its share prices.

https://www.barrons.com/market-data/stocks/mdai

$MDAI trading well today, UP almost 26% on yesterday's News.

“We are pleased to reach this milestone towards the initial commercialization opportunity for our DeepView AI®-Burn algorithm, which contains our first AI software release that can be used for assessment and management of thermal burn wounds,” said Niko Pagoulatos, Ph.D., Chief Operating Officer of Spectral AI. "We look forward to hearing about our application in the first half of 2024.”
https://finance.yahoo.com/news/spectral-submits-application-ukca-mark-143300863.html

$MDAI Spectral AI - Advancing AI-driven Burn Wound Imaging Technology

$MDAI announces the enrollment of the first patient in the pivotal study to validate DeepView AI® using its proprietary imaging technology for burn size and healing assessment. https://www.spectral-ai.com/press-releases/spectral-ai-begins-enrollment-in-pivotal-study-to-validate-deepview-ai-for-burn-injuries/

Spectral AI, Inc. ($MDAI) emerges as a healthcare innovator with a market capitalization surpassing $43.18M. Positioned at the forefront of medical AI, $MDAI's valuation underscores its transformative influence, paving the way for precision in wound care and healthcare excellence.

https://www.morningstar.com/stocks/xnas/mdai/quote

Some great technology...

There is currently no diagnostic tool in the market to be used for burn wounds, and early and reliable assessment of burn severity is critical for better management of burn patients. The predictive software DeepView AI®-Burn seamlessly integrates with our UKCA granted application for our imaging device, DeepViewSnapShot.®

Pump n dump

MDAI Barchart Opinion https://www.barchart.com/stocks/quotes/MDAI/opinion

MDAI WEEKLY https://schrts.co/PcfQNfgA

$MDAI “We are pleased to reach this milestone towards the initial commercialization opportunity for our DeepView AI®-Burn algorithm, which contains our first AI software release that can be used for assessment and management of thermal burn wounds,” said Niko Pagoulatos, Ph.D., Chief Operating Officer of Spectral AI. "We look forward to hearing about our application in the first half of 2024.”

It's trading well today... And lots of rooms to grow to reach the 52 week high.

$MDAI - The DeepView® Wound Imaging System
Multispectral Imaging
Noninvasive diagnostic technology using multispectral imaging to improve outcomes for patients with acute and chronic wounds.
https://www.spectral-ai.com/

MDAI UKCA marking is a product certification system established by the UK government to ensure that products sold in the UK market (England, Wales, and Scotland) comply with relevant laws and technical standards. The DeepView AI®-Burn indication is for individuals aged eighteen years and older. The Company is looking towards expanding its technology to serve pediatric populations and is continuing to initiate case studies and case series with surgeons at leading burn centres.

Spectral AI ($MDAI) shows market momentum with a 52-week range of $1.9 to $19.5. Explore the company's AI-driven solutions in medical diagnostics, particularly in wound care for critical conditions.

https://drive.google.com/file/d/1k_f7knX1L_X4IQunkwUdnsD6K5opzVeV/view

$MDAI - Our Story
Spectral AI is an artificial intelligence company focusing on medical diagnostics, predictive analytics, and ‘Day One’ healing predictions.
https://www.spectral-ai.com/about/

$MDAI This pivotal study is expected to be the final clinical trial before seeking FDA marketing authorization for the burn indication in 2025 and will be conducted in burn centers and emergency departments across the US, enrolling both adults and pediatric patients. https://investors.spectral-ai.com/news-releases/news-release-details/spectral-ai-begins-enrollment-pivotal-study-validate-deepview

$MDAI InvestorsObserver Article January 29, 2024

Thinking about buying stock in Spectral AI, Applied UV ( spectral-ai.com ), Adobe, BigBear.ai, or Aclarion?
https://finance.yahoo.com/news/thinking-buying-stock-spectral-ai-143100334.html
$ADBE $BBAI $AUVI $ACON

Smart move - BWAHAHAHHAHAH

Wensheng Fan, CEO and co-founder of Spectral AI $MDAI , a company that is using artificial intelligence to revolutionize diagnostics and wound care, discusses the recently awarded Biomedical Advanced Research and Development Authority (BARDA) Project BioShield Contract.

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc